Novel Drugs in the Oncology Pipeline 1H 2026

IPD Analytics has released its report “Novel Drugs in the Oncology Pipeline for 1H 2026,” providing an overview of new molecular entities (NMEs) and novel biologics expected to receive FDA approval through NDAs or BLAs in early 2026. The report evaluates how these emerging therapies may influence oncology treatment pathways, payer coverage strategies, and potential budget impact, with most agents anticipated to be administered in the outpatient setting.

These pipeline therapies span multiple oncology indications and are positioned to address unmet clinical needs while reshaping coverage and formulary strategies across managed care organizations. IPD expects the launch pricing for these agents will carry a significant premium, requiring payers to anticipate potential budget impact as clinical adoption expands across eligible patient populations.